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Rupture of a saccular intracranial aneurysm (sIA) is often fatal. Thus, early detection of rupture-prone
sIAs is vital. Myeloperoxidase (MPO), derived mainly from neutrophils, associates with sIA rupture,
and therefore its role in sIA pathogenesis warrants further studies. We analyzed MPO and its
association with other histological markers in 36 (16 unruptured and 20 ruptured) sIA samples by
immunohistochemistry. MPO was present in all studied sIAs, and its expression associated with wall
inflammatory cell infiltrations (r=0.50, 0.63, and 0.75, all p≤0.002), degenerative remodeling (p=0.002)
and rupture (p=0.003). MPO associated strongly with the presence of organized luminal thrombi
(p<0.001), which also stained positive for MPO. Polymorphonuclear MPO+ cells were detected in the
sIA walls, indicating neutrophils as MPO-source. MPO correlated strongly with accumulation of
oxidized lipids (r=0.67, p<0.001) and loss of smooth muscle cells (r=-0.68, p<0.001), suggesting that
MPO is a relevant source of oxidative stress leading to cell death in the sIA wall. Furthermore, MPO
associated with erythrocyte fragmentation (r=0.74, p<0.001) and iron deposition (p=0.041), two
outcomes known to amplify MPO-dependent oxidative stress. Taken together, these results suggest
that MPO associates with degenerative remodeling predisposing to sIA wall rupture and may serve as
a biomarker of a rupture-prone sIA wall.
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Introduction
Rupture of a saccular intracranial aneurysm (sIA) causes intracranial hemorrhage with high mortality
(40-50%) (1). Importantly, unruptured sIAs are common in the population (2-3%) (2, 3), and a fraction
of these sIAs rupture (4). Therefore, understanding sIA pathobiology is essential for development of
new methods that better distinguish and treat sIAs of high rupture risk. Rupture-prone sIA walls show
degenerative remodeling, chronic inflammation, lipid accumulation, and oxidative stress (5-15),
contributing to the cytotoxic microenvironment in the sIA wall (15).
Myeloperoxidase (MPO) is an oxidizing enzyme mainly derived from neutrophils (16-19) and is linked
with the sIA rupture (20). MPO contribution to sIA formation and rupture has also been demonstrated
in a mouse model of induced sIA (21). Here we studied how the MPO expression in the human sIA




We studied a previously published histological series of 36 sIAs (16 unruptured and 20 ruptured,
Supplemental Table 1) (13, 14) resected after clipping the sIA neck at the Department of
Neurosurgery, Helsinki University Hospital, Finland. Clinical data were collected from patients’ medical
records. The Hospital Ethics Committee approved the study protocol.
The tissue samples were treated and immunohistological stainings, imaging, and analysis were
performed as previously described (13, 14). Supplemental Table 2 shows the primary antibodies used
in this study and their concentrations. To analyze the presence of myeloperoxidase (MPO) and matrix
metalloproteinase-9 (MMP-9) in the sIA wall, localization (either intracellular or extracellular in the wall
or in the thrombus) and the extent of expression were scored semiquantitatively (1, 2, 3, or 4) as
described in Figure 1. We additionally defined the degree of colocalization of MPO-expressing areas
with areas of apolipoprotein A-I (apoA-I; the major protein component of for high-density lipoprotein,
HDL) accumulation as complete, partial, or absent.
Statistics
Data analysis was performed using IBM SPSS Statistics Software, version 21 (IBM Corporation). For
categorical variables, proportions were calculated, and Fisher’s exact test was used. For continuous
variables, median and range were calculated, and Mann-Whitney U (MWU) test, Kruskall-Wallis (KW)




MPO associates with degenerative wall remodeling of sIA walls
Myeloperoxidase (MPO)-positive staining was present in all 36 studied saccular intracranial
aneurysms (sIAs) and correlated with loss of smooth muscle cells (SMCs; r=-0.68, p<0.001,
Spearman), a characteristic feature of rupture-prone sIAs (6, 22). Degenerated type C walls showed a
more extensive presence (higher score) of MPO in the sIA wall than those from the less degenerated
types A and B (Figure 2a, Table 1). The MPO score associated with sIA wall rupture (Table 1). MPO
strongly correlated with matrix metalloproteinase-9 (MMP-9; r=0.81, p<0.001, Spearman), which
associated with sIA wall degeneration and rupture (p<0.001, Fisher, Table 1). MPO was expressed in
all fresh or organized thrombi, present in 22/36 (61%) sIAs (Figure 1c and 2b). The presence of
organized luminal thrombi also associated with high MPO score (p<0.001, Fisher). In the sIA wall and
thrombus, MPO was abundant both intracellularly and extracellularly. High MPO score correlated with
the numbers of CD163+ and CD68+ phagocytes and T lymphocytes (Figure 2c-e).
MPO associates with accumulation of erythrocyte degradation products in sIA walls
The MPO score correlated with the accumulation of glycophorin A (GPA; r=0.74, p<0.001, Spearman),
an erythrocyte surface glycoprotein (23), and with the presence of iron (Perl’s blue –positive iron,
hemosiderin; p=0.041, Fisher), known to be derived from the hemoglobin of degraded erythrocytes.
High MPO score was correlated with extensive presence of heme oxygenase 1 (HO-1, r=0.52,
p=0.001, Spearman), a detoxification enzyme induced by erythrocyte-derived heme and oxidative
stress (24-26).
MPO correlates with lipid accumulation in sIA walls
MPO score correlated with accumulation of apolipoprotein B-100 (apoB-100); this accumulation
reflects infiltration of blood plasma –derived apoB-100-containing lipoprotein particles into the sIA wall
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(Figure 3a). Moreover, the MPO score correlated with oxidized, but not neutral, lipids in the sIA walls
(Figure 3b-c). MPO score correlated with the expression of adipophilin, an indicator of intracellular
neutral lipid accumulation (r=0.59, p<0.001, Spearman). Interestingly, the presence of high-density
lipoprotein (HDL) -associated apolipoprotein A-I (apoA-I) particles also correlated with high MPO score
(Figure 3d), and MPO colocalized with apoA-I partly (8/36) or completely (9/36) in 17/36 (47%) sIAs, of
which 14/17 (82%) were ruptured (p=0.013, KW).
Association of MPO with clinical risk factors for IA rupture
A comparison of MPO score with clinical risk factors is shown in Table 2. The MPO score did not
correlate with the various parameters characterizing sIA size, such as base, fundus length, or fundus
width (r=-0.17 to -0.09, p=0.336-0.614, Spearman). MPO score did not associate with smoking or the




In this study, we examined 36 unruptured or ruptured sIAs for the presence of MPO and found that all
sIAs contained MPO. Furthermore, we demonstrated that MPO associates with histological changes
of the sIA wall that are characteristic for degenerative remodeling predisposing to wall rupture.
MPO associates with degenerative remodeling and rupture of sIA walls
MPO was present not only in all studied sIAs, but its expression was also the highest in degenerated
and ruptured sIA walls, thus providing strong suggestive evidence for a role of MPO in the clinically
critical changes in sIA walls. Previously, Gounis et al reported the presence of MPO in three ruptured
and 10/20 unruptured sIAs (20). Chu et al demonstrated increased MPO presence in sIA walls when
compared with the peripheral vascular wall (21). Moreover, in the cited study (21), samples of luminal
blood derived from sIA sacks showed higher MPO concentrations than those of samples derived from
peripheral blood of the patients. In an angiotensin II-elastase-induced mouse model of cerebral
aneurysm, the same group showed that MPO can contribute to aneurysm formation and rupture (21).
Jointly, the above findings and those of the present study imply that MPO plays a role in sIA wall
degeneration and rupture.
In atherosclerotic plaques, MPO causes vascular wall fragility through various mechanisms, including
activation of matrix metalloproteinases (MMPs), which can degrade the extracellular matrix of the
arterial wall (17). Among the several proteases expressed in sIAs (28, 29), MMP-9 is of particular
interest as this protease, similar to MPO, is released by neutrophils during their degranulation (30).
Importantly, released MPO activates the simultaneously released inactive pro-form of MMP-9 (31).
MPO also activates the pro-forms of two other neutrophil-derived MMPs, namely those of MMP-7 and
the neutrophil collagenase MMP-8 (32, 33). Accordingly, in sIAs as in atherosclerotic plaques, MPO
can activate both neutrophil-derived and locally synthesized pro-MMPs, and via such activation can
promote degradation of collagen and elastin fibers. In addition to an increased proteolytic catabolism
of the extracellular matrix of the sIA wall, attenuation of matrix synthesis would also contribute to
reduced tensile strength of the wall. Interestingly, we found that MPO expression in the sIA wall was
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associated with the loss of SMCs, thereby reducing the number of these matrix-synthesizing cells in
the wall. Mechanistically, the finding also suggests that MPO-derived oxidative stress contributes to
the loss of SMCs (34). The presence of cytotoxic microenvironments within the sIA wall is consistent
with the notion that oxidative stress is involved in sIA pathogenesis (15). Since MPO is strongly
oxidizing, it may be a significant contributor of oxidative stress in sIA walls as has been shown in other
vascular pathologies (16-18).
Thrombus as a source for MPO and lysed erythrocytes
We found MPO particularly widespread in the luminal thrombus. In other vascular diseases, the
luminal thrombi trap polymorphonuclear leukocytes (i.e. neutrophils), which produce MPO, often
further stored and delivered by macrophages (18, 34). We observed polymorphonuclear cells in the
thrombi covering the sIA walls; these cells were positive for MPO immunostaining. In addition, also
MPO+ mononuclear cells were also present. Our findings implicate the thrombus, which is often a very
thick layer in the sIA, as the major source for MPO in sIA. MPO expression associated strongly with
increased numbers of CD163+ and CD68+ macrophages, which may also produce MPO (17, 35), or
participate in the storage and release of neutrophil-derived and monocyte/macrophage-derived MPO
in the sIA.
Erythrocytes trapped in an arterial thrombus become lysed and release hemoglobin and other
biologically active components (34, 36, 37). In addition to the luminal thrombus, neovessel-derived
intramural microhemorrhages are another potential source for erythrocytes (13). We showed that the
accumulation of erythrocyte-specific protein GPA correlated with high MPO expression. The cytotoxic
potential of MPO may contribute to lysis of the thrombus-trapped erythrocytes and also oxidize the
released lipid-rich erythrocyte membranes. Furthermore, lysis of erythrocytes releases pro-oxidative
hemoglobin, whose ferrous iron amplifies the pro-oxidative effect of MPO (38). Here, the presence of
iron deposition was associated with high MPO expression, suggesting the presence of a strong
oxidizing environment particularly in the sIAs containing both iron and MPO.
MPO may contribute to accumulation of oxidized lipids in sIA walls
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We have previously shown that lipid accumulation and atherogenic changes occur in sIA walls, and
that these changes associate with degenerative remodeling and wall rupture (12-14). We now
observed that MPO is associated with the extent of immunostaining for apolipoprotein B-100, the
protein component of all atherogenic lipoprotein particles (i.e., of those which transport cholesterol and
other lipids to vascular walls) (39). Moreover, MPO associated with immunostained hydroxynonenal,
which reflects the presence of oxidized lipids (40). In human atherosclerotic lesions, MPO catalyzes
oxidation of lipids and lipoproteins (16-18). Therefore, MPO may also contribute to lipid oxidation also
in the sIA wall.
MPO-dependent oxidation in aortic atheroma plaques is also known to cause dysfunction of the HDL-
mediated cellular cholesterol clearance mechanism by oxidation of apoA-I (41, 42), the major
structural and functional protein of HDL (43). MPO can specifically bind to the apoA-I component of
HDL particles (44). Interestingly, MPO-bound HDL particles are detected in the blood plasma of
patients with abdominal aortic aneurysms (45). Our analysis revealed that nearly half of the studied
sIAs showed either complete or partial colocalization between MPO-positive and apoA-I-positive wall
areas, raising the possibility that in these areas some of apoA-I might have been oxidized by MPO.
Our recent findings demonstrated that intracellular lipid accumulation in SMCs (i.e., SMC foam cell
formation) correlated with apoA-I-positive staining in sIA walls, and that foam cell death had occurred
in degenerated and ruptured sIA walls (14). A fraction of the apoA-I did colocalize with apoE, which
could have immobilized apoA-I in the extracellular matrix of the sIA wall and thus prevented it from
inducing cholesterol efflux from the foam cells (14). The findings of the present study add one potential
mechanism capable of inhibiting the ability of apoA-I to remove cholesterol from foam cells, namely
the MPO-dependent oxidation of apoA-I. Since continuous intracellular accumulation of cholesterol
may trigger death of the foam cells with ensuing inflammation in the sIA wall, dysfunctional apoA-I
could potentially be a promoter of aneurysm wall rupture (14).
MPO as a potential biomarker for a fragile sIA wall
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Contrary to the previous report by Gounis et al (20), in our series of sIAs MPO did not associate with
established clinical risk factors for sIA rupture, such as PHASES score (27) or smoking, despite
association with degenerative wall remodeling and sIA rupture. Thus, our findings suggest that the
widespread presence of MPO may signify a fragile rupture-prone wall also in sIAs that lack the
classical risk factors. MPO can be detected with contrast agent-enhanced MRI (46), and in blood
samples drawn from sIA fundus (21). The lack of correlation between MPO and established risk
factors suggests that MPO may serve as an independent biomarker to assess the risk of sIA rupture.
Conclusion
MPO is present in the sIA wall and may play a role in degenerative wall remodeling and loss of SMCs.
Leukocytes in the luminal thrombus are a major source for MPO, which increases oxidative stress and
accumulation of oxidized lipids in the sIA wall. As MPO associates with degenerative wall remodeling
that predisposes to rupture, but not with the established risk factors for rupture, MPO may serve as an
independent novel biomarker of a rupture-prone sIA.
11
Acknowledgements
We thank Nancy Lim her excellent technical assistance, and Mikko Mäyränpää, MD PhD, Associate
Professor, and Petri Mattila, MD PhD, Associate Professor, for generously providing control tissues.
12
References
1. Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid
haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol
2009;8:635-642
2. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007;369:306-318
3. Vlak MH, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with
emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis.
Lancet Neurol 2011;10:626-636
4. Korja M, Lehto H, Juvela S. Lifelong rupture risk of intracranial aneurysms depends on risk factors:
a prospective Finnish cohort study. Stroke 2014;45:1958-1963
5. Chyatte D, Bruno G, Desai S, et al. Inflammation and intracranial aneurysms. Neurosurgery
1999;45:1137-46; discussion 1146-7
6. Kataoka K, Taneda M, Asai T, et al. Structural fragility and inflammatory response of ruptured
cerebral aneurysms. A comparative study between ruptured and unruptured cerebral aneurysms.
Stroke 1999;30:1396-1401
7. Frösen J, Piippo A, Paetau A, et al. Remodeling of saccular cerebral artery aneurysm wall is
associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke
2004;35:2287-2293
8. Frösen J, Tulamo R, Paetau A, et al. Saccular intracranial aneurysm: pathology and mechanisms.
Acta Neuropathol 2012;123:773-786
9. Tulamo R, Frösen J, Junnikkala S, et al. Complement activation associates with saccular cerebral
artery aneurysm wall degeneration and rupture. Neurosurgery 2006;59:1069-76
10. Tulamo R, Frösen J, Junnikkala S, et al. Complement system becomes activated by the classical
pathway in intracranial aneurysm walls. Lab Invest 2010;90:168-179
11. Tulamo R, Frösen J, Paetau A, et al. Lack of complement inhibitors in the outer intracranial artery
aneurysm wall associates with complement terminal pathway activation. Am J Pathol 2010;177:3224-
3232
13
12. Frösen J, Tulamo R, Heikura T, et al. Lipid accumulation, lipid oxidation, and low plasma levels of
acquired antibodies against oxidized lipids associate with degeneration and rupture of the intracranial
aneurysm wall. Acta Neuropathol Commun 2013;1:71-5960-1-71
13. Ollikainen E, Tulamo R, Frösen J, et al. Mast Cells, Neovascularization, and Microhemorrhages
are Associated With Saccular Intracranial Artery Aneurysm Wall Remodeling. J Neuropathol Exp
Neurol 2014;73:855-864
14. Ollikainen E, Tulamo R, Lehti S, et al. Smooth Muscle Cell Foam Cell Formation, Apolipoproteins,
and ABCA1 in Intracranial Aneurysms: Implications for Lipid Accumulation as a Promoter of Aneurysm
Wall Rupture. J Neuropathol Exp Neurol 2016;75:689-699
15. Laaksamo E, Tulamo R, Liiman A, et al. Oxidative stress is associated with cell death, wall
degradation, and increased risk of rupture of the intracranial aneurysm wall. Neurosurgery
2013;72:109-117
16. Daugherty A, Dunn JL, Rateri DL, et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is
expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444
17. Karakas M, Koenig W. Myeloperoxidase production by macrophage and risk of atherosclerosis.
Curr Atheroscler Rep 2012;14:277-283
18. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease.
Pharmacol Ther 2006;111:16-26
19. Karakas M, Koenig W. Myeloperoxidase production by macrophage and risk of atherosclerosis.
Curr Atheroscler Rep 2012;14:277-283
20. Gounis MJ, Vedantham S, Weaver JP, et al. Myeloperoxidase in human intracranial aneurysms:
preliminary evidence. Stroke 2014;45:1474-1477
21. Chu Y, Wilson K, Gu H, et al. Myeloperoxidase is increased in human cerebral aneurysms and
increases formation and rupture of cerebral aneurysms in mice. Stroke 2015;46:1651-1656
22. Frösen J. Smooth muscle cells and the formation, degeneration, and rupture of saccular
intracranial aneurysm wall--a review of current pathophysiological knowledge. Transl Stroke Res
2014;5:347-356
23. Grant CW, McConnell HM. Glycophorin in lipid bilayers. Proc Natl Acad Sci U S A 1974;71:4653-
4657
14
24. Ishii T, Itoh K, Sato H, et al. Oxidative stress-inducible proteins in macrophages. Free Radic Res
1999;31:351-355
25. Paine A, Eiz-Vesper B, Blasczyk R, et al. Signaling to heme oxygenase-1 and its anti-inflammatory
therapeutic potential. Biochem Pharmacol 2010;80:1895-1903
26. Kikuchi G, Yoshida T, Noguchi M. Heme oxygenase and heme degradation. Biochem Biophys Res
Commun 2005;338:558-567
27. Greving JP, Wermer MJ, Brown RD,Jr, et al. Development of the PHASES score for prediction of
risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. Lancet
Neurol 2014;13:59-66
28. Bruno G, Todor R, Lewis I, et al. Vascular extracellular matrix remodeling in cerebral aneurysms. J
Neurosurg 1998;89:431-440
29. Kurki MI, Häkkinen SK, Frösen J, et al. Upregulated signaling pathways in ruptured human
saccular intracranial aneurysm wall: an emerging regulative role of Toll-like receptor signaling and
nuclear factor-kappaB, hypoxia-inducible factor-1A, and ETS transcription factors. Neurosurgery
2011;68:1667-75
30. Borregaard N, Sehested M, Nielsen BS, et al. Biosynthesis of granule proteins in normal human
bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood 1995;85:812-
817
31. Peppin GJ, Weiss SJ. Activation of the endogenous metalloproteinase, gelatinase, by triggered
human neutrophils. Proc Natl Acad Sci U S A 1986;83:4322-4326
32. Fu X, Kassim SY, Parks WC, et al. Hypochlorous acid oxygenates the cysteine switch domain of
pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic
plaque rupture by myeloperoxidase. J Biol Chem 2001;276:41279-41287
33. Weiss SJ, Peppin G, Ortiz X, et al. Oxidative autoactivation of latent collagenase by human
neutrophils. Science 1985;227:747-749
34. Martin-Ventura JL, Madrigal-Matute J, Martinez-Pinna R, et al. Erythrocytes, leukocytes and
platelets as a source of oxidative stress in chronic vascular diseases: detoxifying mechanisms and
potential therapeutic options. Thromb Haemost 2012;108:435-442
15
35. Sugiyama S, Okada Y, Sukhova GK, et al. Macrophage myeloperoxidase regulation by
granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute
coronary syndromes. Am J Pathol 2001;158:879-891
36. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary
atheroma. N Engl J Med 2003;349:2316-2325
37. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to
rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol
2005;25:2054-2061
38. Michel JB, Martin-Ventura JL, Nicoletti A, et al. Pathology of human plaque vulnerability:
mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis 2014;234:311-319
39. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of
atherosclerosis. Nature 2011;473:317-325
40. Palinski W, Ylä-Herttuala S, Rosenfeld ME, et al. Antisera and monoclonal antibodies specific for
epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis
1990;10:325-335
41. Huang Y, DiDonato JA, Levison BS, et al. An abundant dysfunctional apolipoprotein A1 in human
atheroma. Nat Med 2014;20:193-203
42. Navab M, Reddy ST, Van Lenten BJ, et al. HDL and cardiovascular disease: atherogenic and
atheroprotective mechanisms. Nat Rev Cardiol 2011;8:222-232
43. Annema W, von Eckardstein A, Kovanen PT. HDL and atherothrombotic vascular disease. Handb
Exp Pharmacol 2015;224:369-403
44. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc
Biol 2005;25:1102-1111
45. Delbosc S, Diallo D, Dejouvencel T, et al. Impaired high-density lipoprotein anti-oxidant capacity in
human abdominal aortic aneurysm. Cardiovasc Res 2013;100:307-315
46. DeLeo MJ,3rd, Gounis MJ, Hong B, et al. Carotid artery brain aneurysm model: in vivo molecular
enzyme-specific MR imaging of active inflammation in a pilot study. Radiology 2009;252:696-703
47. Yomantas S, Elner VM, Schaffner T, et al. Immunohistochemical localization of apolipoprotein B in
human atherosclerotic lesions. Arch Pathol Lab Med 1984;108:374-378
16
Figure Legends
Figure 1. Demonstrative images of myeloperoxidase (MPO) and matrix metalloproteinase-9 (MMP-9)
staining patterns in saccular intracranial aneurysm (sIA) walls. To score the extent of MPO
accumulation in the sIA walls, we divided the sIAs into four groups according to the pattern of positive
staining (brown). a, Single scattered positive cells (score 1; n=5/36, 14%, arrowhead); b, positive
staining (intracellular and extracellular) in a restricted wall area (score 2; n=11/36, 31%); c, positive
staining (intracellular and extracellular) in a large area (but less than half of the wall area) (score 3;
n=8/36, 22%, OT stands for organized thrombus); d, majority (more than a half) of the wall area is
positively stained (score 4; n=12/36, 33%, negative control is the inset). For MMP-9, 30/35 sIAs
showed positive staining, and were scored accordingly as follows: e, single scattered positive cells
(score 1; n=12/35, 34%, arrowheads); f, positive staining (intracellular and extracellular) in a restricted
wall area (score 2; n=7/35, 20%); g, positive staining (intracellular and extracellular) in a large area
(but less than half of the wall area) (score 3; n=10/35, 29%). Only 1/35 (3%) of the sIAs showed MMP-
9-positive staining in majority (more than a half) of the wall area (score 4). d, Accumulation of MMP-9-
positive cells in a fresh thrombus (FT, negative control is the inset). The arrows on the right-hand
margin show the wall orientation from the adventitial to the luminal side. The scale bar is 50 μm for a
and e and 100 μm for b-d and f-h.
Figure 2. Association of myeloperoxidase (MPO) with sIA wall degeneration and inflammatory cell
infiltration. a, The extent of MPO (MPO score) in the saccular intracranial aneurysm (sIA) walls
associated with wall type, classified according to previously published criteria (7), where type A
represents a wall with intact endothelium and linearly organized smooth muscle cells (SMCs); type B
represents a thickened wall with disorganized SMCs; type C represents a hypocellular wall with
organizing luminal thrombus; and type D represents a thin sIA wall with organized luminal thrombus.
In this series, only two type-D sIAs were present, thus, these two sIAs were not included in the
analysis due to their small number (13). Panel b shows a demonstrative MPO distribution (green) in
the sIA wall and thrombus (pointing arrows). The negative control is the inset. Polymorphonuclear
MPO+ cells (arrowhead; the squared close-up image) were present in the sIA wall, representing the
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presence of neutrophils. Mononuclear MPO+ cells (star) were also present. MPO score correlated with
the number of the following inflammatory cells: c, CD163+ and d, CD68+ macrophages, and e, CD3+ T
lymphocytes in the sIA wall. The number of inflammatory cells was counted in three standard-sized
(each 0.613 mm2) intensively stained areas (13).
Figure 3. High MPO score in the sIA wall correlated with the following markers of lipid accumulation:
a, apolipoprotein B-100 (apoB-100, an integral protein in low-density lipoprotein, LDL) and b, oxidized
lipid (ox-lipid, hydroxynonenal), but not with c, Oil Red O (ORO)-positive neutral lipid accumulation. d,
Apolipoprotein A-I (apoA-I; the protein component of high-density lipoprotein, HDL) also correlated
with MPO score. The lipid accumulation was measured as the percentage of positively stained area in
the sIA wall (14).
Table 1. Association of myeloperoxidase (MPO) and matrix metalloproteinase-9 (MMP-9) scores with
saccular intracranial aneurysm (sIA) wall type and rupture.











sIAs (n=20) p value†
Number of sIAs (%) Number of sIAs (%)
MPO 0.002* 0.003*
Score 1 2 (22) 3 (25) 0 (0) 5 (31) 0 (0)
Score 2 5 (56) 4 (33) 0 (0) 7 (44) 4 (20)
Score 3 2 (22) 3 (25) 3 (27) 1 (6.3) 7 (35)
Score 4 0 (0) 2 (17) 8 (73) 3 (19) 9 (45)
MMP-9 0.071* <0.001*
Score 0 2 (22) 3 (25) 0 (0) 4 (25) 1 (5)
Score 1 6 (67) 3 (25) 2 (18) 10 (63) 2 (10)
Score 2 1 (11) 2 (17) 3 (27) 1 (6.3) 6 (30)
Score 3 0 (0) 4 (33) 5 (46) 1 (6.3) 9 (45)
Score 4 0 (0) 0 (0) 1 (9) 0 (0) 1 (5)
*p ≤ 0.05 considered significant.
†Fisher's exact test used, proportions are given.
Table 2. Correlation of myeloperoxidase (MPO) expression to clinical risk factors of saccular intracranial aneurysm











Population Finnish Finnish Finnish Finnish
Hypertension† n (%) 4 (80) 2 (18) 2 (25) 4 (33) 0.141
Age‡ 55 (49-66) 54 (29-67) 63 (41-87) 47 (24-74) 0.239
Size (mm)‡
Base 3.6 (3.0-5.0) 4.0 (2.5-8.0) 4.5 (3.0-11.0) 3.0 (1.6-5.5) 0.288
Fundus lenght 5.5 (4.7-12.5) 6.5 (5.0-18.6) 9.5 (4.0-12.5) 6.0 (2.2-10.0) 0.317
Fundus width 5.3 (3.0-8.5) 5.0 (3.0-13.0) 7.3 (3.5-12.5) 4.8 (3.5-7.0) 0.372
Earlier subarachnoid
hemorrhage† 1 0 1 0 0.124
Site†§ 0.618
MCA (n=21) 3 6 5 7
AcomA (n=7) 2 3 1 1
PcomA (n=3) 0 2 1 0
ICA (n=3) 0 0 1 2
Other (n=2) 0 0 0 2
PHASES Score‡|| 13 (8-14) 10 (7-13) 13 (8-14) 7 (5-15) 0.019*
Current smoking† (%) 4 (80) 7 (64) 4 (50) 3 (25) 0.161
Serum cholesterol value (mmol/L)‡
Total cholesterol 5.4 (4.2-7.1) 5.6 (4.3-5.9) 5.7 (4.8-6.6) 5.4 (3.8-6.2) 0.626
LDL-cholesterol 2.8 (2.2-4.8) 2.9 (2.1-3.9) 2.7 (2.2-4.3) 2.6 (1.7-3.9) 0.707
Triglyserides 1.5 (1.1-2.7) 1.2 (0.6-2.2) 0.9 (0.6-5.4) 2.0 (1.0-3.5) 0.563
HDL-cholesterol 1.5 (1.1-1.7) 1.8 (1.5-2.0) 2.1 (0.9-3.0) 1.5 (1.3-1.7) 0.237
*p ≤ 0.05 considered significant.
†Fisher's exact test used, proportions are given.
‡Kruskall Wallis test used, median and range are given for continuous variables.
2
§MCA, middle cerebral artery; AcomA, anterior communicans artery; PcomA, posterior communicans artery; ICA,
internal carotid artery; Other, one posterior inferior cerebellar artery and one ophtalmic artery sIA.
||Population, Hypertension, Age, Size, Earlier SAH, and Site (27).
